FLUMAZENIL

First approved in 1991

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H14FN3O3
Molecular Weight	303.2884
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1

InChI

InChIKey=OFBIFZUFASYYRE-UHFFFAOYSA-N

InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C15H14FN3O3
Molecular Weight	303.2884
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB01205
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cdi/flumazenil.html

Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system. Fumazenil is used for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, and where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures. Also for the management of benzodiazepine overdose as an adjunct for appropriate supportive and symptomatic measures. Flumazenil went off patent in 2008 so at present generic formulations of this drug are available.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
GABA-A receptor; anion channel 203 Target ID: CHEMBL2093872 Sources: http://www.drugbank.ca/drugs/DB01205	Antagonist 2849
GABA receptor alpha-1 subunit 19 Target ID: CHEMBL1962 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=18973287	Antagonist 2849	3.3 nM [Ki]
GABA-A receptor; alpha-6/beta-3/gamma-2 6 Target ID: CHEMBL2095190 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10633039	Antagonist 2849	148.0 nM [Ki]
Gamma-aminobutyric acid receptor subunit gamma-2 2 Target ID: P18507 Gene ID: 2566.0 Gene Symbol: GABRG2 Target Organism: Homo sapiens (Human) Sources: http://www.drugbank.ca/drugs/DB01205	Antagonist 2849
GABA receptor alpha-3 subunit 6 Target ID: CHEMBL3026 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18973287	Antagonist 2849	8.1 nM [Ki]
GABA receptor alpha-2 subunit 7 Target ID: CHEMBL4956 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18973287	Antagonist 2849	5.7 nM [Ki]
GABA receptor alpha-4 subunit 2 Target ID: CHEMBL2472 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18973287	Antagonist 2849	2.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Benzodiazepine overdose 1 Sources: https://www.drugs.com/pro/flumazenil-injection.html	Secondary		Approved 8583	FLUMAZENIL Approved Use Flumazenil Injection, USP is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. Launch Date 2004

C_max

Value	Dose	Analyte	Population
45.9 ng/mL EXPERIMENT https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf	0.2 mg single, intravenous dose: 0.2 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FLUMAZENIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6.98 ng/mL EXPERIMENT https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf	2.2 mg single, sublingual dose: 2.2 mg route of administration: Sublingual experiment type: SINGLE co-administered:	FLUMAZENIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.28 ng/mL EXPERIMENT https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf	2.2 mg single, sublingual dose: 2.2 mg route of administration: Sublingual experiment type: SINGLE co-administered:	FLUMAZENIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT

AUC

Value	Dose	Analyte	Population
12.9 ng × h/mL EXPERIMENT https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf	0.2 mg single, intravenous dose: 0.2 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FLUMAZENIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12 ng × h/mL EXPERIMENT https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf	2.2 mg single, sublingual dose: 2.2 mg route of administration: Sublingual experiment type: SINGLE co-administered:	FLUMAZENIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
9.1 ng × h/mL EXPERIMENT https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf	2.2 mg single, sublingual dose: 2.2 mg route of administration: Sublingual experiment type: SINGLE co-administered:	FLUMAZENIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT

T_1/2

Value	Dose	Analyte	Population
1.18 h EXPERIMENT https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf	0.2 mg single, intravenous dose: 0.2 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FLUMAZENIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.05 h EXPERIMENT https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf	2.2 mg single, sublingual dose: 2.2 mg route of administration: Sublingual experiment type: SINGLE co-administered:	FLUMAZENIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.12 h EXPERIMENT https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf	2.2 mg single, sublingual dose: 2.2 mg route of administration: Sublingual experiment type: SINGLE co-administered:	FLUMAZENIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT

Doses

Dose	Population	Adverse events
3 mg single, intravenous Highest studied dose Dose: 3 mg Route: intravenous Route: single Dose: 3 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1647443/	unhealthy, 32-62 Health Status: unhealthy Age Group: 32-62 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/1647443/	Sources: https://pubmed.ncbi.nlm.nih.gov/1647443/
7.13 mg single, intravenous Recommended Dose: 7.13 mg Route: intravenous Route: single Dose: 7.13 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/	unhealthy, 35.2 years (range: 17-75 years) Health Status: unhealthy Age Group: 35.2 years (range: 17-75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/	Other AEs: Injection site pain, Agitation... Other AEs: Injection site pain (10.3%) Agitation (8%) Anxiety (3.4%) Crying abnormal (3.4%) Headache (3.4%) Vomiting (3.4%) Tachycardia (3.4%) Dizziness (3.4%) Nausea (2.3%) Convulsions (1.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/
1 mg single, intravenous Recommended Dose: 1 mg Route: intravenous Route: single Dose: 1 mg Sources: https://pubmed.ncbi.nlm.nih.gov/9695999/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9695999/	Sources: https://pubmed.ncbi.nlm.nih.gov/9695999/

AEs

AE	Significance	Dose	Population
Convulsions	1.1%	7.13 mg single, intravenous Recommended Dose: 7.13 mg Route: intravenous Route: single Dose: 7.13 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/	unhealthy, 35.2 years (range: 17-75 years) Health Status: unhealthy Age Group: 35.2 years (range: 17-75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/
Injection site pain	10.3%	7.13 mg single, intravenous Recommended Dose: 7.13 mg Route: intravenous Route: single Dose: 7.13 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/	unhealthy, 35.2 years (range: 17-75 years) Health Status: unhealthy Age Group: 35.2 years (range: 17-75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/
Nausea	2.3%	7.13 mg single, intravenous Recommended Dose: 7.13 mg Route: intravenous Route: single Dose: 7.13 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/	unhealthy, 35.2 years (range: 17-75 years) Health Status: unhealthy Age Group: 35.2 years (range: 17-75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/
Anxiety	3.4%	7.13 mg single, intravenous Recommended Dose: 7.13 mg Route: intravenous Route: single Dose: 7.13 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/	unhealthy, 35.2 years (range: 17-75 years) Health Status: unhealthy Age Group: 35.2 years (range: 17-75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/
Crying abnormal	3.4%	7.13 mg single, intravenous Recommended Dose: 7.13 mg Route: intravenous Route: single Dose: 7.13 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/	unhealthy, 35.2 years (range: 17-75 years) Health Status: unhealthy Age Group: 35.2 years (range: 17-75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/
Dizziness	3.4%	7.13 mg single, intravenous Recommended Dose: 7.13 mg Route: intravenous Route: single Dose: 7.13 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/	unhealthy, 35.2 years (range: 17-75 years) Health Status: unhealthy Age Group: 35.2 years (range: 17-75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/
Headache	3.4%	7.13 mg single, intravenous Recommended Dose: 7.13 mg Route: intravenous Route: single Dose: 7.13 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/	unhealthy, 35.2 years (range: 17-75 years) Health Status: unhealthy Age Group: 35.2 years (range: 17-75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/
Tachycardia	3.4%	7.13 mg single, intravenous Recommended Dose: 7.13 mg Route: intravenous Route: single Dose: 7.13 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/	unhealthy, 35.2 years (range: 17-75 years) Health Status: unhealthy Age Group: 35.2 years (range: 17-75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/
Vomiting	3.4%	7.13 mg single, intravenous Recommended Dose: 7.13 mg Route: intravenous Route: single Dose: 7.13 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/	unhealthy, 35.2 years (range: 17-75 years) Health Status: unhealthy Age Group: 35.2 years (range: 17-75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/
Agitation	8%	7.13 mg single, intravenous Recommended Dose: 7.13 mg Route: intravenous Route: single Dose: 7.13 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/	unhealthy, 35.2 years (range: 17-75 years) Health Status: unhealthy Age Group: 35.2 years (range: 17-75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8239101/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
activator 150 inducer 1087

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CES1 45 P-gp 2052	CYP2B6 669 CYP1A2 832

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	activator 342 Sources: https://www.covance.com/content/dam/covance/assetLibrary/posters/EricksonISSX15.pdf	no
CYP1A2 2333	inducer 1966 Sources: https://www.covance.com/content/dam/covance/assetLibrary/posters/EricksonISSX15.pdf	no
CYP2B6 1160	activator 342 Sources: https://www.covance.com/content/dam/covance/assetLibrary/posters/EricksonISSX15.pdf	no
CYP2B6 1160	inducer 1966 Sources: https://www.covance.com/content/dam/covance/assetLibrary/posters/EricksonISSX15.pdf	no
CYP3A4 2633	activator 342 Sources: https://pubmed.ncbi.nlm.nih.gov/28062541/ \| https://www.covance.com/content/dam/covance/assetLibrary/posters/EricksonISSX15.pdf	no
CYP3A4 2633	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/28062541/ \| https://pubmed.ncbi.nlm.nih.gov/29969338/ \| https://www.covance.com/content/dam/covance/assetLibrary/posters/EricksonISSX15.pdf	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CES1 45	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10942971/	yes
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/22455873/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5103	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5103
ChemicalBook	CB9208108	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9208108
eMolecules	538442	https://www.emolecules.com/cgi-bin/more?vid=538442
MolPort	MolPort-003-666-855	https://www.molport.com/shop/molecule-link/MolPort-003-666-855
Selleck Chemicals	Flumazenil	http://www.selleckchem.com/products/Flumazenil.html
ZINC	ZINC000000001464	http://zinc15.docking.org/substances/ZINC000000001464

PubMed

Title	Date	PubMed
Voluntary self-poisoning as a cause of admission to a tertiary hospital internal medicine clinic in Piraeus, Greece within a year.	2001	11602022
Comparison of N2O- and chlordiazepoxide-induced behaviors in the light/dark exploration test.	2001 Apr	11526978
Different sensitivities to competitive inhibition of benzodiazepine receptor binding of 11C-iomazenil and 11C-flumazenil in rhesus monkey brain.	2001 Apr	11448072
Benzodiazepines protect against ethanol-induced gastric mucosal damage in vitro.	2001 Aug	11564131
Neurophysiological effects of an extract of Eschscholzia californica Cham. (Papaveraceae).	2001 Aug	11507727
Different types of GABA(A) receptors may mediate the anticonflict and response rate-decreasing effects of zaleplon, zolpidem, and midazolam in squirrel monkeys.	2001 Aug	11498724
Changes in mACh, NMDA and GABA(A) receptor binding after lateral fluid-percussion injury: in vitro autoradiography of rat brain frozen sections.	2001 Aug	11483644
Influence of benzodiazepine binding site ligands on fear-conditioned contextual memory.	2001 Aug 24	11525770
Delayed synaptic dysfunction of association cortices in carbon monoxide intoxication.	2001 Dec	11761490
Dual-[11C]tracer single-acquisition positron emission tomography studies.	2001 Dec	11740210
Chronic benzodiazepine treatment of cells expressing recombinant GABA(A) receptors uncouples allosteric binding: studies on possible mechanisms.	2001 Dec	11739624
The midazolam-induced paradox phenomenon is reversible by flumazenil. Epidemiology, patient characteristics and review of the literature.	2001 Dec	11737177
Brain function in social anxiety disorder.	2001 Dec	11723629
Involvement of benzodiazepine binding sites in an antiaggressive effect by 5-HT(1A) receptor activation in isolated mice.	2001 Dec 7	11740952
Binding of [3H]CB 34, a selective ligand for peripheral benzodiazepine receptors, to rat brain membranes.	2001 Dec 7	11740947
Asymmetrical localization of benzodiazepine receptors in the human auditory cortex.	2001 Jan	11349799
Disturbed benzodiazepine receptor function at the onset of temporal lobe epilepsy--lomanzenil-binding in de-novo TLE.	2001 Jul	11518000
A fluorescent receptor assay for benzodiazepines using coumarin-labeled desethylflumazenil as ligand.	2001 Jul 1	11467569
Sleep inducing effects of propofol microinjection into the medial preoptic area are blocked by flumazenil.	2001 Jul 27	11454326
GABAergic and glutamatergic modulation of exploratory behavior in the dorsomedial hypothalamus.	2001 Jul-Aug	11509219
Visual event-related potentials in cirrhotic patients without overt encephalopathy: the effects of flumazenil.	2001 Jun	11726088
Interactions between LY354740, a group II metabotropic agonist and the GABA(A)-benzodiazepine receptor complex in the rat elevated plus-maze.	2001 Jun	11448091
A small dose of midazolam decreases the time to achieve hypnosis without delaying emergence during short-term propofol anesthesia.	2001 Jun	11435052
The effects of flumazenil on sleepiness, task performance and nocturnal sleep after anesthesia with midazolam.	2001 Jun	11422855
Diazepam poisoning with one-month monitoring of diazepam and nordiazepam blood levels.	2001 Jun	11383664
Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors.	2001 Jun 15	11516422
Relationship of flumazenil and glucose PET abnormalities to neocortical epilepsy surgery outcome.	2001 Jun 26	11425929
Melatonin enhances Th2 cell mediated immune responses: lack of sensitivity to reversal by naltrexone or benzodiazepine receptor antagonists.	2001 May	11506187
Modification of the effects of benzodiazepines on the exploratory behaviors of mice on a hole-board by diabetes.	2001 May	11430472
Behavioral effects of agents active at the gamma-aminobutyric acid receptor complex in the staircase paradigm.	2001 May 18	11368960
The inability of CCK to block (or CCK antagonists to substitute for) the stimulus effects of chlordiazepoxide.	2001 May-Jun	11420071
Neuroreceptor bindings and synaptic activity in visual system of monocularly enucleated rat.	2001 May-Jun	11369376
Estimation of regional cerebral blood flow levels in ischemia using [(15)O]water of [(11)C]flumazenil PET without arterial input function .	2001 May-Jun	11351197
The negative GABA(A) modulator methyl beta-carboline-3-carboxylate attenuates the behavioral effects of the positive GABA(A) modulators triazolam and pregnanolone in rhesus monkeys.	2001 Nov	11713619
Confluence of antianalgesic action of diverse agents through brain interleukin(1beta) in mice.	2001 Nov	11602679
Effect of diazepam binding inhibitor (DBI) on the fluid intake, preference and the taste reactivity in mice.	2001 Nov 29	11704264
[Functional imaging (PET and SPECT) in epilepsy].	2001 Nov 4	11766233
Benzodiazepines in the intensive care unit.	2001 Oct	11762264
Benzodiazepine-GABA(A) receptor binding is very low in dysembryoplastic neuroepithelial tumor: a PET study.	2001 Oct	11737168
Prolonged vigabatrin treatment modifies developmental changes of GABA(A)-receptor binding in young children with epilepsy.	2001 Oct	11737167
Biodistribution, binding specificity and metabolism of [18F]fluoroethylflumazenil in rodents.	2001 Oct	11578902
A change in the density of [(3)H]flumazenil, but not [(3)H]muscimol binding, in Brodmann's Area 9 from subjects with bipolar disorder.	2001 Oct	11578667
2-Arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides. New potent and selective peripheral benzodiazepine receptor ligands.	2001 Oct	11557354
Nutritional parameters modify muricidal behavior of male Wistar rats: preventive effects of amino acids and 4' Cl diazepam.	2001 Oct 26	11720079
Synergistic interaction of diazepam with 3',5'-cyclic adenosine monophosphate-elevating agents on rat aortic rings.	2001 Oct 5	11675045
Dose-dependent enhancement of in vivo GABA(A)-benzodiazepine receptor binding by isoflurane.	2001 Sep	11575528
The effects of flumazenil, Ro 154513 and beta-CCM on the behaviour of control and stressed mice in the staircase test.	2001 Sep	11565621
SPECT and neuropsychological performance in severe depression treated with ECT.	2001 Sep	11532532
Anxiolytic effect of Kami-Shoyo-San (TJ-24) in mice: possible mediation of neurosteroid synthesis.	2001 Sep 21	11669460
Binding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative/hypnotic.	2002 Jan 2	11755161

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Reversal of Sedation Initial dose: 0.2 mg IV one time over 15 seconds. Repeated doses: 0.2 mg may be given every minute until the desired level of consciousness is achieved. Maximum total dose 1 mg. Most patients respond to 0.6 to 1 mg.

Route of Administration: Intravenous

In Vitro Use Guide

Exposure (48 h) of human embryonic kidney (HEK) 293 cells stably expressing recombinant alpha1beta2gamma2S GABAA receptors to flumazenil (1 or 5 uM) in the presence of GABA (1 uM) enhanced the maximum number (Bmax) of [3H]flunitrazepam binding sites without affecting their affinity (Kd).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:48:43 GMT 2025` Edited by `admin` on `Mon Mar 31 17:48:43 GMT 2025`
Record UNII	40P7XK9392
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ANEXATE

Preferred Name

English

FLUMAZENIL

Official Name

English

FLUMAZENIL [USAN]

Common Name

English

RO-15-1788

Code

English

FLUMAZENIL [MI]

Common Name

English

FLUMAZEPIL

Common Name

English

Flumazenil [WHO-DD]

Common Name

English

MAZICON

Brand Name

English

FLUMAZENIL [USP-RS]

Common Name

English

FLUMAZENIL [VANDF]

Common Name

English

Ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate

Systematic Name

English

RO-151788

Code

English

FLUMAZENIL [MART.]

Common Name

English

RO-151788000

Code

English

NSC-759193

Code

English

RO 15-1788/000

Code

English

RO-1722

Code

English

FLUMAZENIL [EP MONOGRAPH]

Common Name

English

FLUMAZENIL [ORANGE BOOK]

Common Name

English

LANEXAT

Brand Name

English

FLUMAZENIL [USP MONOGRAPH]

Common Name

English

ROMAZICON

Brand Name

English

4H-IMIDAZO(1,5-A)(1,4)BENZODIAZEPINE-3-CARBOXYLIC ACID, 8-FLUORO-5,6-DIHYDRO-5-METHYL-6-OXO-, ETHYL ESTER

Common Name

English

flumazenil [INN]

Common Name

English

RO-15-1788/000

Code

English

FLUMAZENIL [JAN]

Common Name

English

RO-41-8157

Code

English

Classification Tree Code System Code

WHO-ATC

V03AB25